Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of TSN1611 in advanced solid tumors with KRAS G12D mutation
CTR20241863Phase 2Active
- Sponsor
- Taily Bio
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TSN1611 in Nonhematologic neoplasms, colorectal cancer (CRC), pancreatic cancer (PC), bronchial carcinoma, sponsored by Taily Bio. Started Jun 2024; status: active.
02
Drugs
TSN1611
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)pancreatic cancer (PC)bronchial carcinoma
Beyond the preview
Go deeper on CTR20241863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241863.